The FDA has granted traditional approval to pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma ...

IGV-001, an investigational autologous cell immunotherapeutic combination product, may offer clinically meaningful overall ...

Dr. Peter Voorhees discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk ...

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Sacituzumab tirumotecan demonstrated a 31% objective response rate and 71% disease control rate in advanced urothelial ...

Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...

Che-Kai Tsao, MD, MS, system chief of Solid Tumor Oncology at Northwell Health Cancer Institute, discusses new approaches that could change the standard of care for metastatic hormone-sensitive ...

The FDA has granted fast track designation to zotiraciclib (TG02), an oral central nervous sytem-penetrant multikinase inhibitor, for treatment of patients with recurrent high-grade gliomas (rHGG) ...

Vorasidenib significantly reduced tumor growth rates in IDH1/2-mutant grade 2 glioma, improving PFS and TTNI compared to ...

Naxitamab plus GM-CSF demonstrated strong antitumor activity and manageable toxicity in high-risk neuroblastoma patients, ...

DS-1594b showed on-target biological activity but failed to achieve protocol-defined responses, leading to early trial termination. Differentiation syndrome occurred in 29.4% of patients, prompting ...

Historically, there was no clear standard of care nor regulatory approvals for therapy for SMM prior to the AQUILA study. The ...